The present disclosure relates to a herbo-mineral metallic pharmaceutical kit and a process for its preparation. The herbo-mineral metallic pharmaceutical kit comprises Suvarna Bhasmadi Vati (SBV), Mouktikyukta Kamdudha Vati (MKV), Trailokyachintamani Rasa Vati (TCR), Kumari Kalpa Vati (KKV) and Khadirarishta (KHA). The herbo-mineral metallic pharmaceutical kit of the present disclosure can be used for delaying and/or controlling the recurrence or occurrence of breast and/or ovarian cancer in second breast and/or ovary or metastasis. The herbo-mineral metallic pharmaceutical compositions of the kit assist in reducing oxidative stress, improving immune status and quality of life and maintaining a disease-free survival in patients who are genetically predisposed to breast or ovarian cancer.

The present disclosure relates to a herbo-mineral metallic pharmaceutical kit and a process for its preparation. The herbo-mineral metallic pharmaceutical kit comprises Suvarna Bhasmadi Vati (SBV), Mouktikyukta Kamdudha Vati (MKV), Trailokyachintamani Rasa Vati (TCR), Kumari Kalpa Vati (KKV) and Khadirarishta (KHA). The herbo-mineral metallic pharmaceutical kit of the present disclosure can be used for delaying and/or controlling the recurrence or occurrence of breast and/or ovarian cancer in second breast and/or ovary or metastasis. The herbo-mineral metallic pharmaceutical compositions of the kit assist in reducing oxidative stress, improving immune status and quality of life and maintaining a disease-free survival in patients who are genetically predisposed to breast or ovarian cancer.

The present disclosure provides a nutritional formula comprising alpha-lactalbumin enriched whey protein concentrate; beta-casein enriched milk protein; mildly hydrolyzed milk protein; osteopontin; lactoferrin; oleic acid-palmitic acid-oleic acid triglyceride, wherein palmitic acid is at the SN-2 position of the glycerol backbone of the triglyceride; lactose, wherein the lactose is reduced lactose; lutein; docosahexanoic acid; arachidonic acid; galactooligosaccharides; and polydextrose. The provided nutritional formulas may be useful in providing nutrition and/or promoting postnatal development of a subject (e.g., promoting postnatal development of an infant's gastrointestinal functions, nutrient absorption, immune system development, etc.). Also provided are powder forms, reconstituted formulas, kits, methods, and uses that include or involve a nutritional formula described herein.

The present disclosure provides a nutritional formula comprising alpha-lactalbumin enriched whey protein concentrate; beta-casein enriched milk protein; mildly hydrolyzed milk protein; osteopontin; lactoferrin; oleic acid-palmitic acid-oleic acid triglyceride, wherein palmitic acid is at the SN-2 position of the glycerol backbone of the triglyceride; lactose, wherein the lactose is reduced lactose; lutein; docosahexanoic acid; arachidonic acid; galactooligosaccharides; and polydextrose. The provided nutritional formulas may be useful in providing nutrition and/or promoting postnatal development of a subject (e.g., promoting postnatal development of an infant's gastrointestinal functions, nutrient absorption, immune system development, etc.). Also provided are powder forms, reconstituted formulas, kits, methods, and uses that include or involve a nutritional formula described herein.

A nutritional composition comprises fucosylated human milk oligosaccharide and/or sialylated human milk oligosaccha-ride, non-digestible, fermentable polysaccharide, and Bifidobacterium. The nutritional composition is free of short-chain fructooligosac-charide having at least about 50% of molecules with a degree of polymerization of less than about 5. A method of treating a subject at risk of developing a Clostridium difficile infection or a subject having a Clostridium difficile infection comprises administering such a nutritional composition.

A nutritional composition comprises fucosylated human milk oligosaccharide and/or sialylated human milk oligosaccha-ride, non-digestible, fermentable polysaccharide, and Bifidobacterium. The nutritional composition is free of short-chain fructooligosac-charide having at least about 50% of molecules with a degree of polymerization of less than about 5. A method of treating a subject at risk of developing a Clostridium difficile infection or a subject having a Clostridium difficile infection comprises administering such a nutritional composition.

The present invention relates to a composition/formulation for reducing uremic toxins, particularly protein bound uremic toxins in chronic kidney disease (CKD). More particularly, the pharmaceutical composition/formulation comprises a synergistic combination of Inulin and Betaine or their pharmaceutically acceptable salts for reducing protein bound uremic toxins. The present application also provides various compositions/formulations and process of preparing the same.

The present invention relates to a composition/formulation for reducing uremic toxins, particularly protein bound uremic toxins in chronic kidney disease (CKD). More particularly, the pharmaceutical composition/formulation comprises a synergistic combination of Inulin and Betaine or their pharmaceutically acceptable salts for reducing protein bound uremic toxins. The present application also provides various compositions/formulations and process of preparing the same.

The invention relates to a novel glucose polymer which is particularly useful for administration by the parenteral route, and to the method for the production thereof. The invention also relates to compositions comprising such a glucose polymer, and to the methods for the production thereof. The invention further relates to the use thereof as a medicament, for example as an osmotic agent for peritoneal dialysis.

The invention relates to a novel glucose polymer which is particularly useful for administration by the parenteral route, and to the method for the production thereof. The invention also relates to compositions comprising such a glucose polymer, and to the methods for the production thereof. The invention further relates to the use thereof as a medicament, for example as an osmotic agent for peritoneal dialysis.